Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease

Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease

Abstract Background Epoetin beta pegol (continuous erythropoietin receptor activator; C.E.R.A.) is currently widely used for the treatment of anemia associated with chronic kidney disease (CKD). Therapeutic control of anemia is assessed by monitoring haemoglobin (Hb) levels. However, certain qualita...

Full description

Bibliographic Details
Main Authors: Ken Aizawa, Ryohei Kawasaki, Yoshihito Tashiro, Yasushi Shimonaka, Michinori Hirata
Format: Article
Language:English
Published: BMC 2018-01-01
Series:BMC Nephrology
Subjects:
Epoetin beta pegol (C.E.R.A.)
Chronic kidney disease (CKD)
Anemia
Hematopoiesis
Erythrocyte deformability
Erythrocyte turnover
Online Access:http://link.springer.com/article/10.1186/s12882-018-0818-4

Internet

http://link.springer.com/article/10.1186/s12882-018-0818-4

Similar Items